Fusion glycoprotein

Fusion glycoprotein 분자 정보

영어 이름Respiratory syncytial virus F protein시판 약물 수3
임상 약물 수5표적 별명Protein F,F,Fusion glycoprotein F0
최고 연구 개발 단계Approved
영어 이름Respiratory syncytial virus F protein
표적 별명Protein F,F,Fusion glycoprotein F0
시판 약물 수3
임상 약물 수5
최고 연구 개발 단계Approved

Fusion glycoprotein 제품 목록

  • 속성

    Antibody (2)Protein (1)

  • 제품 라이브러리

    온라인 (3)

  • 종

    Mouse (2)Nipah virus (1)

  • 태그

    - (2)His Tag (1)

  • 마커

    Unconjugated (2)Biotin-labeled (1)

Fusion glycoprotein분자 배경

Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.

Fusion glycoprotein분자 별명

Fusion glycoprotein, F protein, F, Nipah virus, Hendra virus

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
CPI-RSV-F VaccineBLB-201Phase 2 ClinicalBlue Lake Biotechnology IncRespiratory Syncytial Virus Infections
상세
RSV vaccine (Vaxart)Phase 1 ClinicalVaxart Biosciences IncRespiratory Syncytial Virus Infections
상세
GR-2102GR2102; GR-2102Phase 1 ClinicalChongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co LtdRespiratory Syncytial Virus Infections
상세
Palivizumab biosimilar (mAbxience)MB-05Phase 1 ClinicalMabxience Sa
상세
RSM-01Phase 1 ClinicalBill & Melinda Gates Medical Research InstituteRespiratory Syncytial Virus Infections
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
NirsevimabAnti-RSV-mAb-D25; SP-0232; MEDI-8897; Anti-RSV MAb-YTEApprovedAimm Therapeutics, MedImmune Inc, SanofiBeyfortus, 乐唯初EURespiratory Syncytial Virus InfectionsSanofi Winthrop Industrie SA2022-10-31Lower Respiratory Tract Infections; Respiratory Syncytial Virus Infections
상세
PalivizumabABT-315; MEDI-493ApprovedAbbvie Inc, Medimmune LlcSynagisUnited StatesRespiratory Syncytial Virus InfectionsSwedish Orphan Biovitrum Ab (Publ)1998-06-19Bronchiolitis; Bronchopulmonary Dysplasia; Heart Defects, Congenital; Infant, Premature, Diseases; Premature Birth; Respiratory Syncytial Virus Infections
상세
Respiratory syncytial virus immune globulinRSV-IGIVApprovedMedimmuneRespiGamUnited StatesRespiratory Syncytial Virus Infectionsnull1996-01-01Respiratory Syncytial Virus Infections
상세
  • 분자 정보
  • 제품 목록
  • 시판 약물 정보
  • 임상 약물 정보